UNSPSC 51382303: Feclobuzone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C27H25ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6889JIL5D, chemically known as 4-chlorbenzoesaeure ester mil 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidindion but generally known as feclobuzone, which bears US NIH Compound Identifier 176165. European Medicines Agency schedules Feclobuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07523MIG.

UNSPSC 51382303 Feclobuzone, a Commodity code, does not align with the recent state and local opportunities posted under this classification. The three identified solicitations — Seminole County's procurement of naloxone and drug deactivation systems, the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescriptions, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and over-the-counter products — involve pharmaceutical procurement, pharmacy benefit program management, and emergency response medications, but none specifically reference feclobuzone or closely related pharmaceutical products. The code shows little relevant recent activity relative to what state and local governments are actively buying in the pharmaceutical and emergency response space.

Geographic activity spans multiple states and jurisdictions: Seminole County in Florida, the Texas Health and Human Services Commission statewide, and Minnesota (administering MMCAP, which serves participating state and local governments including Oregon). The Seminole County IFB (IFB60459723LAS) with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas RFI (HHS0017013), posted April 3, 2026, is exploratory market research into direct-to-manufacturer prescription programs. The Minnesota RFP (S1070000015802), with a response deadline of March 26, 2026, establishes multi-vendor contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with contract terms effective July 1, 2026. The mismatch between the feclobuzone commodity code and the actual pharmaceutical procurement activity documented suggests either a cataloging error or that this code tier does not capture the full scope of pharmaceutical commodities state and local governments purchase.